RaQualia infectious, neurology, gastrointestinal news

RaQualia said it will reduce headcount by about 12 (14%) to 70 in 2013 to focus on four compounds in early stage development for gastrointestinal diseases. The cuts include the elimination of nine R&D-related positions. RaQualia said it also will replace its president, Naoki

Read the full 442 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE